InsiderGlobe

KROS

insider transactions

Keros Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).

30D 90D 1Y

Net shares · 365d

-16.8K

22.5K buy · 39.3K sell

Net value · 365d

-$219.3K

$406.3K in · $625.6K out

Sentiment · 365d

Net selling

39% buying · 61% selling

Open-market trades · 365d

20

22.5K buy · 39.3K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

About KROS insider trading

This page tracks insider transactions for Keros Therapeutics, Inc. (KROS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.

We may use privacy-friendly analytics to understand aggregate traffic. See our Privacy Policy.